All In Biotech

Drug Trial Radar · NCT05794230

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,528 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,528

Actual

Start

Mar 27, 2023

Primary completion

Nov 15, 2025

Study completion Nov 15, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks, up to 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This open label randomized study will be conducted to evaluate and/or describe the immunogenicity and describe the safety of MenACYW conjugate vaccine when administered in infants and toddlers. It will be conducted in India and the RSA in 2 cohorts: * Cohort I: Infants and toddlers 6 months to 16 months of age (Cohort I) * Cohort II: Infants and toddlers 6 weeks to 15 months of age (Cohort II) In Cohort I, eligible participants will be randomized in a 1:1 ratio to receive 2 intramuscular (IM) injections (1+1 vaccination schedule) of either MenACYW conjugate vaccine (Groups 1 and 3) or Menactra vaccine (Groups 2 and 4), co-administered with routine pediatric vaccines. In Cohort II, eligible participants will be randomized in a 2:1 ratio to receive either 3 IM injections (2+1 vaccination schedule) of MenACYW conjugate vaccine co-administered with routine pediatric vaccines (Groups 5 and 7) or routine pediatric vaccines only (Groups 6 and 8). The primary objectives of this study are: * To demonstrate the non-inferiority of immunogenicity of 2 doses of MenACYW conjugate vaccine compared to 2 doses of Menactra® vaccine in infants and toddlers 6 months to 16 months of age (Cohort I) in terms of serum bactericidal assay using human complement (hSBA) seroprotection (titers ≥ 1:8) in India and the Republic of South Africa (RSA) * To demonstrate the vaccine immune sufficiency of 3 doses of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age (Cohort II) in terms of hSBA seroprotection (titers ≥ 1:8) in India and the RSA The secondary objectives of this study are: * To describe the antibody titers to the meningococcal serogroups A, C, Y, and W: * before and 30 days post primary series of MenACYW conjugate vaccine and before and 30 days post booster dose of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age (Cohort II) in India and the RSA when administered concomitantly with other age-recommended vaccines. * before and after 30 days post each dose of MenACYW conjugate vaccine or Menactra vaccine in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA when administered concomitantly with other age-recommended vaccines. * To describe the antibody responses against the antigens of the other age-recommended vaccines when administered concomitantly with MenACYW conjugate vaccine: * in infants and toddlers 6 weeks to 15 months of age (Cohort II) in India and the RSA. * in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA. * To describe the safety profile of MenACYW conjugate vaccine and that of licensed Menactra vaccine in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA when administered concomitantly with other age-recommended vaccines. * To describe the safety profile of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of age (Cohort II) in India and the RSA when administered concomitantly with other age-recommended vaccines. * To describe the safety profile of age-recommended vaccines: * in infants 6 weeks to 15 months of age (Cohort II) in India and the RSA when administered concomitantly with MenACYW conjugate vaccine. * in infants and toddlers 6 months to 16 months of age (Cohort I) in India and the RSA when administered concomitantly with MenACYW conjugate vaccine. The duration of each participant's active participation in the study will be approximately 10 to 11 months for Cohort I and 13,5 to 14,5 months for Cohort II.

Conditions

  • Meningococcal Immunisation
  • Healthy Volunteers

Interventions

  • Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineBiological

    Liquid solution - intramuscular

  • Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological

    Liquid solution - intramuscular

  • Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)Biological

    Oral suspension - oral

  • Pneumoccocal VaccineBiological

    Suspension for injection - intramuscular

  • Measles, Mumps, and Rubella Vaccine live (MMR)Biological

    Lyophilized powder for injection - subcutaneous

  • DTwP-HepB-Hib-IPV vaccineBiological

    Suspension - intramuscular

  • DTaP-IPV-Hib-HepB vaccineBiological

    Liquid solution - intramuscular

  • Hepatitis A vaccineBiological

    Lyophilized powder for injection - subcutaneous

  • Rotavirus vaccineBiological

    Oral solution - oral

  • Typhoid conjugate vaccine (TCV)Biological

    Suspension for injection - intramuscular

  • Measles vaccineBiological

    Freeze-dried powder for reconstitution and injection - subcutaneous

  • Varicella vaccine liveBiological

    Sterile powder and diluent for injection - subcutaneous

  • Varicella vaccine liveBiological

    Lyophilized powder for injection - subcutaneous

  • Measles, Mumps, and Rubella Vaccine live (MMR)Biological

    Lyophilized powder for injection - subcutaneous

  • Hepatitis A vaccineBiological

    Suspension for injection - intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with anti-meningococcal serogroups A, C, Y, W antibody titers above predefined thresholds after 2 doses of MenACYW conjugate vaccine compared to 2 doses of Menactra® vaccine in infants and toddlers 6 months to 16 months of ageTime frame: 30 days after the second vaccination
  2. Percentage of participants with anti-meningococcal serogroups A, C, Y, W Ab titers above predefined thresholds after 3 doses of MenACYW conjugate vaccine in infants and toddlers 6 weeks to 15 months of ageTime frame: 30 days after the booster vaccination

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 3560006

    Chennai, India

  • Investigational Site Number : 3560007

    Hyderabad, India

  • Investigational Site Number : 3560016

    Kanpur, India

  • Investigational Site Number : 3560009

    Kolkata, India

  • Investigational Site Number : 3560011

    Manipal, India

  • Investigational Site Number : 3560013

    Mysore, India

  • Investigational Site Number : 3560004

    Mysore, India

  • Investigational Site Number : 3560003

    New Delhi, India

  • Investigational Site Number : 3560002

    Pune, India

  • Investigational Site Number : 3560001

    Pune, India

  • Investigational Site Number : 7100002

    Cape Town, South Africa

  • Investigational Site Number : 7100003

    Cape Town, South Africa

  • Investigational Site Number : 7100006

    George, South Africa

  • Investigational Site Number : 7100005

    Johannesburg, South Africa

  • Investigational Site Number : 7100001

    Middelburg, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.